CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy.
Joint Bone Spine
; 91(5): 105702, 2024 Sep.
Article
in En
| MEDLINE
| ID: mdl-38336271
ABSTRACT
Chimeric Antigen Receptor T-cell therapy (CAR-T), currently employed routinely for treating B-cell malignancies, has emerged as a groundbreaking approach in addressing severe autoimmune diseases, especially for systemic lupus erythematosus (SLE). The immunological rationale for targeting B lymphocytes in autoimmune diseases is well-established, demonstrating success in numerous autoantibody-mediated autoimmune conditions through targeted therapies over several years. However, this approach has often proven ineffective in the context of systemic lupus erythematosus. Recent data on CAR-T usage in lupus, revealed promising results including rapid and prolonged remission without treatment, highlighting the potential of CAR-T therapy in severe lupus cases. This article provides a comprehensive overview of CAR-T cells, tracing their evolution from hematological malignancies to their recent applications in autoimmune disorder, especially in lupus. Clinical trials within a regulated framework are now imperative to assess the procedural aspects in order to validate the considerable promise of CAR-T cell therapy in the field of autoimmune diseases. This includes evaluating safety and long-term efficacy and security of the procedure, the benefit-risk ratio in the field of autoimmunity, the availability and cost-related issues associated with this emerging cellular therapy procedure.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Immunotherapy, Adoptive
/
Lupus Erythematosus, Systemic
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Joint Bone Spine
Journal subject:
REUMATOLOGIA
Year:
2024
Type:
Article